Kelly Doyle
No Rating Available
(Learn About Our Rating System)

Kelly Doyle, PhD, DABCC, FAACC

Languages spoken: English, Portuguese, Spanish

  • Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

    Specialties

    • Pathology, Clinical

    Board Certification

    American Board of Clinical Chemistry

  • Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

    Board Certification and Academic Information

    Academic Departments Pathology -Associate Professor (Clinical)
    Board Certification
    American Board of Clinical Chemistry

    Education history

    Fellowship Clinical Chemistry - University of Utah School of Medicine Fellow
    Research Fellow Oncology and Medicinal Chemistry - Huntsman Cancer Institute, Center for Investigational Therapeutics Postdoctoral Research Fellow
    Doctoral Training Medicinal Chemistry - University of Utah Ph.D.
    Undergraduate Chemistry - Utah State University B.S.

    Selected Publications

    Journal Article

    1. Allison TR, Laulu SL, Doyle K, Nelson HA (2025). Evaluation of preanalytical factors on quantification of amyloid-β (1-42), phosphorylated tau 181, and total tau in cerebrospinal fluid. Lab Med. (Read full publication)
    2. Saadalla A, Doyle K, Moser K, Smock K (2025). Determination of Fibrinogen Ratio Cutoff Limits Using Indirect Reference Interval Methodology. Int J Lab Hematol. (Read full publication)
    3. Nelson HA, Condie C, Doyle K, Rudolf JW, Pearson LN (2025). On-Cell Stability of Digoxin, Lithium, Phenytoin, Valproic Acid, and Vancomycin for Therapeutic Drug Monitoring. J Appl Lab Med. (Read full publication)
    4. Nelson HA, Doyle K, Straseski JA (2025). TSH Receptor Antibody Test Utilization Patterns from a National Reference Laboratory: TRAb, TSI, or Both? J Clin Endocrinol Metab. (Read full publication)
    5. Bahr TM, Doyle K, Ohls RK, Christensen RD (2025). Using the refineR algorithm to generate indirect reference intervals for newborn infants for the parameters "Micro-R" and "HYPO-He". J Perinatol. (Read full publication)
    6. Zilka S, Wei R, Payto D, Doyle K, Hockings J, Coln-Franco JM (2024). Analytical and operational considerations of measuring glucose 6-phosphate dehydrogenase (G6PD) activity using a fully automated assay. Am J Clin Pathol, 163(1), 153-160. (Read full publication)
    7. Zilka S, Wei R, Payto D, Doyle K, Hockings J, Coln-Franco JM (2024). Measurement of Glucose 6-Phosphate Dehydrogenase (G6PD) Activity Using a Fully Automated Assay: Analytical and Operational Considerations. Am J Clin Pathol, 163(1), 153-160.
    8. Mathewson NJ, Pearson LN, Doyle K (2023). Abnormal Hb A1c Result from a Diabetic Patient Leads to Unexpected Diagnosis. Clin Chem, 69(7), 684-687. (Read full publication)
    9. Ammer T, Schtzenmeister A, Rank CM, Doyle K (2022). Estimation of Reference Intervals from Routine Data Using the refineR Algorithm-A Practical Guide. J Appl Lab Med, 8(1), 84-91. (Read full publication)
    10. Erickson JA, Chiang FI, Walker CM, Genzen JR, Doyle K (2022). Comparison of two chromogranin A assays and investigation of nonlinear specimens. Pract Lab Med, 32, e00299. (Read full publication)
    11. Nelson HA, Laulu SL, Lu J, Doyle K (2021). Mitigation of Biotin Interference in Manual and Automated Immunoassays by Preconjugating Biotinylated Antibodies to the Streptavidin Surface as an Alternative to Biotin Depletion. J Appl Lab Med, 7(3), 762-775. (Read full publication)
    12. Nelson HA, Laulu S, Lu J, Doyle K (2022). Mitigation of Biotin Interference in Manual and Automated Immunoassays by Pre-Conjugating Biotinylated Antibodies to the Streptavidin Surface as an Alternative to Biotin Depletion. J Appl Lab Med, 7(3), 762-775.
    13. Doyle K, Frank EL (2021). Verifying Clinically Derived Reference Intervals for Daily Excretion Rates of Fractionated Metanephrines Using Modern Indirect Reference Interval Models. Am J Clin Pathol, 156(4), 691-699.
    14. Doyle K, Frank EL (2021). Verifying Clinically Derived Reference Intervals for Daily Excretion Rates of Fractionated Metanephrines Using Modern Indirect Reference Interval Models. Am J Clin Pathol, 156(4), 691-699. (Read full publication)
    15. Doyle K (2020). Commentary on Extreme Hyperglycemia in an Elderly Patient. Clin Chem, 67(5), 729. (Read full publication)
    16. Kroner GM, Johnson-Davis KL, Doyle K, McMillin GA (2019). Cannabinol (CBN) Cross-Reacts with Two Urine Immunoassays Designed to Detect Tetrahydrocannabinol (THC) Metabolite. J Appl Lab Med, 5(3), 569-574. (Read full publication)
    17. cAlthaus, T, Lubell, Y, Maro, V P, Mmbaga, B T, Lwezaula, B, Halleux, C, Biggs, H M, Galloway, R L, Stoddard, R A, Perniciaro, J L, Nicholson, W L, Doyle K, Olliaro, P, Crump, J A, Rubach, M P (2020). Sensitivity of C-reactive Protein for the Identification of Patients with Laboratory-Confirmed Bacterial Infections in Northern Tanzania. Trop Med Int Health, 25(3), 291 - 300.
    18. Bahr TM, Christensen RD, Ward DM, Meng F, Jackson LK, Doyle K, Christensen DR, Harvey AG, Yaish HM (2019). Ferritin in serum and urine: A pilot study. Blood Cells Mol Dis, 76, 59-62. (Read full publication)
    19. Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma S (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924. (Read full publication)
    20. Natali R, Wand C, Doyle K, Noguez JH (2018). Evaluation of a new venous catheter blood draw device and its impact on specimen hemolysis rates. Pract Lab Med, 10, 38-43. (Read full publication)
    21. Doyle K, Strathmann FG (2017). Cost and Efficacy Assessment of an Alternative Medication Compliance Urine Drug Testing Strategy. Pain Med, 18(2), 307-315. (Read full publication)
    22. Marin SJ, Doyle K, Chang A, Concheiro-Guisan M, Huestis MA, Johnson-Davis KL (2016). One Hundred False-Positive Amphetamine Specimens Characterized by Liquid Chromatography Time-of-Flight Mass Spectrometry. J Anal Toxicol, 40(1), 37-42. (Read full publication)
    23. Doyle K, Fitzpatrick FA (2010). Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J Biol Chem, 285(23), 17417-24. (Read full publication)
    24. Cordray P, Doyle K, Edes K, Moos PJ, Fitzpatrick FA (2007). Oxidation of 2-Cys-peroxiredoxins by arachidonic acid peroxide metabolites of lipoxygenases and cyclooxygenase-2. J Biol Chem, 282(45), 32623-9. (Read full publication)

    Review

    1. Doyle K, Bunch DR (2023). Reference intervals: past, present, and future. [Review]. Crit Rev Clin Lab Sci, 60(6), 466-482. (Read full publication)
    2. Kushnir MM, Nelson HA, Doyle K (2021). Clinical Utility and Analytical Aspects of Direct Measurements of Free Hormones Using Mass Spectrometry-Based Methods. [Review]. J Appl Lab Med, 7(4), 945-970. (Read full publication)
    3. Johnson-Davis KL, Doyle K (2019). Therapeutic Drug Monitoring in Pregnant Patients. [Review]. Ther Drug Monit, 42(2), 172-180. (Read full publication)

    Commentary

    1. Doyle K (2021). Commentary on Extreme Hyperglycemia in an Elderly Patient. Clin Chem, 67(5), 729.

    Other

    1. Doyle K (2018). Parkin Function in Parkinson’s Disease. Clin Chem (64(11), p. 1676).

    Patent

    1. Hariprasad VM, Bearss D, Mollard A, Doyle K, Currie S, Sharma S, Graves B (2012). Substituted 1H-Pyrazolo-Pyrimidin and Pyridine Series of ETS Family Transcription Factor Inhibiting Compounds.